1. Home
  2. DBVT vs MEGI Comparison

DBVT vs MEGI Comparison

Compare DBVT & MEGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DBV Technologies S.A.

DBVT

DBV Technologies S.A.

N/A

Current Price

$9.02

Market Cap

692.2M

Sector

Health Care

ML Signal

N/A

Logo MainStay CBRE Global Infrastructure Megatrends Term Fund

MEGI

MainStay CBRE Global Infrastructure Megatrends Term Fund

N/A

Current Price

$13.61

Market Cap

740.6M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
DBVT
MEGI
Founded
2002
N/A
Country
France
United States
Employees
90
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
692.2M
740.6M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
DBVT
MEGI
Price
$9.02
$13.61
Analyst Decision
Buy
Analyst Count
7
0
Target Price
★ $36.51
N/A
AVG Volume (30 Days)
★ 300.2K
130.7K
Earning Date
10-28-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 10.26
N/A
EPS
N/A
★ N/A
Revenue
★ $5,636,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1,837.59
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 35.77
N/A
52 Week Low
$8.63
$13.25
52 Week High
$26.19
$15.89

Technical Indicators

Market Signals
Indicator
DBVT
MEGI
Relative Strength Index (RSI) 37.71 31.32
Support Level $8.78 $13.25
Resistance Level $12.41 $15.45
Average True Range (ATR) 0.76 0.31
MACD -0.12 -0.09
Stochastic Oscillator 0.97 0.00

Price Performance

Historical Comparison
DBVT
MEGI

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund

NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income, focusing on the investment megatrends of decarbonization, digital transformation, and asset modernization.

Share on Social Networks: